Opinion
Video
Evolving Strategies in Adjuvant HER2+ Breast Cancer
Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy seeks an update on adjuvant therapy based on preoperative responses, prompting Isaacs to share insights. The standard of care for patients with residual disease involves the KATHERINE regimen with T-DM1 (trastuzumab emtansine), showing significant benefits in progression-free and overall survival (OS). McArthur further discusses the impressive data from the KATHERINE trial, which revealed a substantial increase in invasive disease-free survival and an overall survival advantage after 8.4 years of follow-up. Notably, the trial demonstrated consistent benefits across various patient subgroups.
O’Shaughnessy expresses emotional astonishment at the separation in survival curves, emphasizing the profound impact of T-DM1. McArthur underscores the need for continued research, acknowledging that despite the substantial progress, 1 in 5 women with residual disease still experiences recurrence. The discussion highlights the importance of tailoring therapy based on response, considering factors such as nodal involvement, and reflects on the evolving landscape of HER2-positive breast cancer treatment.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
